-
Study aim
-
Determining the effect of gabapentin as an assistive treatment in chronic nonbacterial prostatitis
-
Design
-
A pre- and a post-intervention clinical trial with an intervention group of 100 patients, without a control group, non-blinded.
-
Settings and conduct
-
Patients will be selected in a simple randomized manner, and the patient's age and information about the symptoms and about The factors that contribute to chronic non-bacterial prostatitis will be asked. an informed consent form is provided to the patient and our study will begin. Then, along with other prescription drugs, the patient will receive gabapentin capsules produced by Abidi Company at a dose of 100 mg orally twice daily. The treatment period will be 12 weeks. At the end of the course, patients will be given a response to treatment with a score of 1 to 10.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria:
-Age of 18 years old or more
-Having pain in one or more this areas: groin,hypo-gastric, back pain, testis, penis, lower back, anal, and the area between the scrotum and anus for at least three months.
-Having one or more of the following urinary symptoms: dysuria, frequency, delay at the beginning of urination, enuresis, the urgency.
-Painful ejaculation
-Erectile dysfunction
exclusion criteria:
-Chronic bacterial prostatitis
-Acute prostatitis
-Dissatisfied to participate in the study
-Allergy to gabapentin
-
Intervention groups
-
Intervention group: adding Gabapentin to the usual treatment of patients with non-bacterial chronic prostatitis
Control group: without a control group
-
Main outcome variables
-
Reducing pain in chronic non-bacterial prostatitis